157 -4 (66) 2024 - Ibadullaeva N.S., Кazakova E.I. - JN.1 VARIANT OF SARS-CoV-2 PROPOSING INTEREST FOR MONITORING

JN.1 VARIANT OF SARS-CoV-2 PROPOSING INTEREST FOR MONITORING

Ibadullaeva N.S. The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Кazakova E.I. The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Lokteva L.M. The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Xusanov A.M. The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Nurmatov V.X. Republican Specialized Hospital Zangiota-1, Uzbekistan

Resume

Despite the cancellation of the WHO COVID-19 pandemic status, tracking circulating SARS-CoV-2 strains is still relevant. This article presents the results of SARS-CoV-2 sequencing of samples received for February 2024 from the Zangiota-1 Republican Specialised Hospital. JN.1 variant of SARS-CoV-2, classified by WHO as a variant of interest, was detected in all samples.

Keywords: COVID-19, SARS-CoV-2, JN.1, mutation, sequencing.

First page

860

Last page

863

For citation: Ibadullaeva N.S., Кazakova E.I., Lokteva L.M., Xusanov A.M., Nurmatov V.X. - JN.1 VARIANT OF SARS-CoV-2 PROPOSING INTEREST FOR MONITORING//New Day in Medicine 4(66)2024 860-863 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Tracking SARS-CoV-2 variants. https://www.who.int/activities/tracking-SARS-CoV-2-variants.
  2. Meo S.A., Meo A.S., Klonoff D.C. Omicron new variant BA.2.86 (Pirola): Epidemiological, biological, and clinical characteristics - a global data-based analysis // Eur Rev Med Pharmacol Sci. 2023 Oct;27(19):9470-9476.
  3. Uriu K., Ito J., Kosugi Y., Tanaka Y.L. et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant // Lancet Infect. Dis. 2023; 23: e460-e461.
  4. Lasrado N., Collier A.Y., Hachmann N.P., Miller J. et al. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86 // Vaccine. 2023; 41: 6904-6909.
  5. Sheward D.J., Yang Y., Westerberg M., Öling S. et al. Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses // Lancet Infect. Dis. 2023; 23: e462-e463.
  6. Yang S., Yu Y., Jian F. et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect Dis. 2023; 23: e457-e45.
  7. Wang Q., Guo Y., Liu L. et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike // Nature. 2023; https://doi.org/10.1038/s41586-023-06750-w9.
  8. Uriu K Ito J Kosugi Y et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant // Lancet Infect Dis. 2023; 23: e460-e461.
  9. Cao Y., Song W., Wang L. et al. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75 // Cell Host Microbe. 2022; 30: 1527-1539.
  10. Wang Q Li Z Guo Y et al. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 // iScience. 2023; 26108254.

    file

    download